A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors

Haemophilia

Volumn 15, Issue 2, 2009, Pages 405-419

  Knight, Cris ^a   Dano A M ^b   Kennedy martin, T ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b NOVO NORDISK A S   (Denmark)

^c KMHO   (United Kingdom)

Author keywords

APCC; Cost effectiveness; Cost utility; Haemophilia; rFVIIa; Systematic review

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DOSE RESPONSE; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; HEMOPHILIA; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

BLOOD COAGULATION FACTORS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FACTOR VIIA; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MALE; RECOMBINANT PROTEINS;

EID: 63349083417     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01969.x     Document Type: Review

References (31)

1. Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press, 2006.
2. Drummond M, O'Brien B, Stoddart G et.al. Methods for the economic evaluation of health care programmes, 3rd edn. Oxford: Oxford University Press, 2005.
3. National Institute for Clinical Excellence (NICE). The Guidelines Manual. London: NICE, 2007.
4. Ekert H, Brewin T, Boey W, Davey P, Tilden D. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX. Haemophilia 2001; 7: 279-85.
5. Knight C, Paisley S, Wight J, Lloyd-Jones M. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003; 9: 521-40.
6. EuroQoL Group. EuroQol: A new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
7. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnoses and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
8. Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 1998; 63: 7-10.
9. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2356-63.
10. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE, 2004.
11. Scottish Medicines Consortium (SMC). Guidance to manufacturers for completion of New Product Assessment Form (NPAF). 2006. Available at: http://www.scottishmedicines.org.uk/smc/33.html (last accessed on 22 January 2008).
12. Joshi AV, Stephens JM, Munro V, Mathew P, Botteman MF. Pharmacoeconomic analysis of recombinant Factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Curr Med Res Opin 2006; 22: 23-31.
13. Odeyemi I, Guest J. Modelling the economic impact of recombinant activated Factor VII and activated prothrombin-complex concentrate in the treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX at a comprehensive care centre in the UK. J Med Econ 2002; 5: 51-64.
14. Odeyemi IA, Guest JF. Modelling the economic impact of recombinant activated Factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX in the UK. J Med Econ 2002; 5: 119-33.
15. Huth-Kuehne A, Lages P, Zimmeermann R. The impact of rebleeds in cost modelling of treatment strategies in patients with haemophilia A and inhibitors. Blood (ASH Annual Meeting Abstracts) 2006; 108: 4046.
16. Hilgartner M, Aledort LM, Andes A, Gill J, and the members of the FEIBA Study Group. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion 1990; 30: 626-30.
17. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant Factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
18. Chung K, Berger A, Edelsberg J, Neufeld E, Oster G Cost-effectiveness of FEIBA for the treatment of mild-to-moderate bleeds in hemophilia patients with inhibitors. Abstracts of the XXVIth International Congress of The World Federation of Hemophilia. Haemophilia 2004; 10: 1-163.
19. Carlsson KS, Astermark J, Donfield SM, Berntorp E. Health-economic analysis of alternative bypassing agents in haemophilia complicated by an inhibitor -the FEIBA ® NovoSeven ® Comparative Study (FENOC). Blood (ASH Annual Meeting Abstracts) 2006; 108: 457.
20. Astemark J, Donfield SM, BiMichele DM et.al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
21. Santagostino E, Gringeri G, Mannucci P. Home treatement with recombinant activated factor VII in patients with factor VIII inhibitors: The advantages of early intervention. Br J Haematol 1999; 104: 22-6.
22. Key NS, Laurian Y. Comparison of two studies on the use of Novoseven in home treatment of mild to moderate bleeding episodes in haemophiliacs with inhibitors. Haemophilia 1998; 4: 241 (abstract 342).
23. Ozelo MC, Villaca PR, De Almeida JOSC et al. A csot evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil. Haemophilia 2007; 13: 462-9.
24. Dundar S, Zulfikar B, Kavaklik B et al. A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey. J Med Econ 2005; 8: 45-54.
25. Yoo SK, Yong LS, Kyu PS, Woo YC. Pharmaco-economic evaluation of treatment alternatives for mild to moderate bleeding episodes in patients with haemophilia with inhibitors in Korea. Abstract from the XX1st International Society on Thrombosis and Haemostasis Congress 2007. Thromb Haemost 2007; 5(Suppl. 2): P-W-158.
26. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor FVIII and factor IX inhibitors. French FEIBA Study Group. Factor eight bypassing activity. Thromb Haemost 1997; 77: 1113-9.
27. Putnam KG, Bohn RL, Ewenstein BM, Winkelmayer WC, Avorn J. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. Haemophilia 2005; 11: 261-9.
28. Seremetis S, Joshi AV, Asmussen M. Cost minimization model for treatment of minor bleeding episodes in inhibitor patients -methodological issues. Haemophilia 2006; 12: 108-9.
29. -1 dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: A randomized comparison. Haemophilia 2007; 14: 287-94.
30. Treur MJ, McCracken F, Heeg B et al. Efficacy of recombinant activated factor VII (rFVIIa) vs. activated prothrombin complex concentrate (APCC) in patients with hemophilia with inhibitors: A Bayesian meta-analysis. Blood (ASH Annual Meeting Abstracts) 2007; 110: 3964.
31. Lusher JM. Acute hemarthroses: The benefits of early versus late treatment with recombinant activated factor VII. Blood Coag Fibrinol 2000; 11(Suppl. 1): S45-9.